Clinical Trials
Aduro’s lead program, a combination immunotherapy comprised of its novel GVAX Pancreas and CRS-207 technologies, is being evaluated in a 240-patient Phase 2b ECLIPSE trial in patients with metastatic pancreatic cancer.

CONTINUE READING »
Technology
Aduro is harnessing the immune system to treat cancer.  Aduro's technologies are designed to activate both innate and adaptive immunity to generate a potent and long-lasting response against cancer.   

CONTINUE READING »
News
  • April, 09 2014  | Congratulations to Dr. Elizabeth Jaffee on selection to lead Stand Up To Cancer (SU2C)-Lustgarten Foundation Pancreatic Cancer Convergence Dream Team  READ IT HERE
  • April, 08 2014  | Congratulations to Drs. Dung Le and Todd Crocenzi for award of 2014 Pancreatic Cancer Action Network-AACR Research Acceleration Network Grant  READ IT HERE
  • March, 07 2014  | Dirk Brockstedt presents at the 11th Annual International Symposium on Malignant Mesothelioma (first presentation on video, ends at 15:45)  WATCH IT HERE
  • February, 20 2014  | Immunotherapy Duo Improves Survival in Metastatic Pancreatic Cancer  READ IT HERE
  • February, 19 2014  | Chief Executive Officer, Stephen Isaacs presents at BIO CEO & Investor Conference (registration required to view video)  WATCH IT HERE
  • February, 10 2014  | Aduro BioTech announces initiation of Phase 2b ECLIPSE trial to evaluate treatment of patients with pancreatic cancer with the company’s innovative immunotherapies  READ IT HERE
SEE MORE NEWS »
Copyright 2011-2013 Aduro Biotech. All rights reserved.
Privacy Policy  |  Terms of Use